{"id":89911,"date":"2021-04-16T17:49:16","date_gmt":"2021-04-16T16:49:16","guid":{"rendered":"https:\/\/clarivate.com\/?p=89911"},"modified":"2024-10-24T00:26:57","modified_gmt":"2024-10-24T00:26:57","slug":"from-connected-pens-to-artificial-pancreases-how-innovative-technology-is-transforming-the-diabetes-treatment-landscape","status":"publish","type":"post","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/blog\/from-connected-pens-to-artificial-pancreases-how-innovative-technology-is-transforming-the-diabetes-treatment-landscape\/","title":{"rendered":"From connected pens to artificial pancreases: how innovative technology is transforming the diabetes treatment landscape"},"content":{"rendered":"

Clarivate medtech experts Usman Syed and Lucy Guan share findings from their analysis of the diabetes market<\/a> and discuss how partnerships and innovation are transforming treatment options for diabetes patients.\u00a0<\/i><\/p>\n

The demand for diabetes care devices is being fueled by the drastic increase in the number of Americans with diabetes<\/a>, coupled with the serious and costly consequences of poor condition management (e.g., heart disease, neuropathy, kidney disease, wounds, worse post-surgical outcomes) and inadequate access to care due to expensive insurance plans with high copays.<\/p>\n

As a result, patient care currently\u00a0revolves around the most affordable diabetes care products, such as traditionally more commoditized devices for multiple daily injections (MDI; syringes, durable pens) and self-monitoring blood glucose (SMBG) devices. Uptake of newer, innovative but higher-priced devices has therefore been somewhat slow.<\/p>\n

However, manufacturers, third-party digital health companies and payers still aim to provide better solutions to reduce patient burden, enhance management adherence and improve patient lives. Novel devices that provide superior ease-of-use and simplify diabetes management appeal to patients, while those that improve treatment compliance and reduce costly complications appeal to payers, even when they come at a premium price.<\/p>\n

For example, a number of competitors have recently introduced pre-calibrated continuous glucose monitoring (CGM) devices that eliminate the need for daily finger prick calibrations. Companies are also developing closed-loop systems that partially automate adjustments to insulin delivery in response to blood glucose levels, which will significantly simplify diabetes management for patients.<\/p>\n

Table 1.<\/strong>\u00a0Significant innovation is occurring in the U.S. diabetes care device market<\/span><\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Product type<\/strong><\/td>\nBrand<\/strong><\/td>\nCompany<\/strong><\/td>\nLaunch date<\/strong><\/td>\nStatus<\/strong><\/td>\n<\/tr>\n<\/thead>\n
CGM\u00a0Devices<\/td>\nFreestyle Libre 3<\/p>\n

 <\/p>\n

 <\/p>\n

 <\/p>\n

 <\/p>\n

 <\/p>\n

 <\/p>\n

G7\u00a0CGM\u00a0Device<\/td>\n

Abbott<\/p>\n

 <\/p>\n

 <\/p>\n

 <\/p>\n

 <\/p>\n

 <\/p>\n

 <\/p>\n

Dexcom Inc<\/td>\n

Expected 2021<\/p>\n

 <\/p>\n

 <\/p>\n

 <\/p>\n

 <\/p>\n

 <\/p>\n

 <\/p>\n

Expected 2021<\/td>\n

The device has received CE marking in Europe, and the company is awaiting FDA approval<\/p>\n

 <\/p>\n

The company has begun clinical trials in the U.S.<\/td>\n<\/tr>\n

 <\/p>\n

SugarBEAT<\/td>\n

 <\/p>\n

Nemaura Pharma Ltd<\/td>\n

 <\/p>\n

Expected 2021<\/td>\n

 <\/p>\n

The device has received CE marking in Europe, and the company is awaiting FDA approval<\/td>\n<\/tr>\n

WaveForm CGM Device<\/td>\nWaveForm Technologies Inc<\/td>\nExpected 2021\u20132022<\/td>\nThe device has received CE marking in Europe, and the company is preparing for FDA submission<\/td>\n<\/tr>\n
Eversense XL\u00a0CGM\u00a0System<\/td>\nSenseonics Holdings<\/td>\nExpected 2021\u20132022<\/td>\nThe 180-day system has received CE marking in Europe, and the company has begun clinical trials in the U.S.<\/td>\n<\/tr>\n
Eclipse ICGM<\/td>\nGlySens Inc<\/td>\nUnknown<\/td>\nCurrently undergoing development<\/td>\n<\/tr>\n
UBAND\u00a0CGM<\/td>\nKnow Labs Inc<\/td>\nUnknown<\/td>\nCurrently undergoing development<\/td>\n<\/tr>\n
Unknown<\/td>\nLifeScan Inc and Sanvita Medical LLC<\/td>\nUnknown<\/td>\nCurrently undergoing development<\/td>\n<\/tr>\n
Insulin Pumps<\/td>\nPaQ<\/td>\nCeQur<\/td>\nExpected 2021<\/td>\nThe patch pump has received CE marking in Europe, and the company is awaiting FDA approval<\/td>\n<\/tr>\n
Omnipod Horizon<\/td>\nInsulet Corp<\/td>\nExpected 2021<\/td>\nThe company is awaiting FDA approval<\/td>\n<\/tr>\n
MiniMed 780G Insulin Pump<\/td>\nMedtronic<\/td>\nExpected 2021<\/td>\nThe company is preparing for FDA submission<\/td>\n<\/tr>\n
Bigfoot Loop<\/td>\nBigfoot Biomedical Inc<\/td>\nExpected 2021<\/td>\nThe company is preparing for FDA submission<\/td>\n<\/tr>\n
iLet<\/td>\nBeta Bionics Inc<\/td>\nExpected 2021\u20132022<\/td>\nCurrently undergoing clinical evaluation<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n

Source:<\/strong> 2021 Diabetes Care Devices – Market Insights – United States (Clarivate)<\/span><\/p>\n

 <\/p>\n

Integrated devices, such as closed-loop systems, gain popularity, with a number of new launches and partnerships<\/h3>\n

Medtronic\u2019s MiniMed 670G<\/strong><\/a>\u2014the first “artificial pancreas” system\u2014represented a significant step forward in diabetes care when it was launched in 2017. The closed-loop system combines both CGM and insulin delivery technology in a single device, responding to the patient\u2019s insulin needs in real time by monitoring glucose levels and automatically adjusting insulin delivery. Although adoption was initially hindered by its high cost, increased coverage by insurance companies improved its affordability. Since then, Medtronic has developed additional models within the family and launched its next-generation hybrid closed-loop Mini Med 780G<\/strong> in the summer of 2020 with CE marking in Europe.<\/p>\n

In December 2019, Tandem Diabetes Care\u2019s t:slim X2<\/strong><\/a> insulin pump with Control-IQ advanced hybrid closed-loop technology was approved for use by the FDA. This represented the first interoperable automated glycemic controller device approved by the FDA and paved the way for integrated CGMs and alternate controller-enabled (ACE) insulin pumps to be used with interoperable automated glycemic controllers as a complete automated insulin dosing (AID) system. When launched, the integration of the t:slim X2 with Dexcom’s G6<\/strong> CGM enabled automated correction boluses within an AID system.<\/p>\n

Other strategic partnerships aimed at pairing insulin delivery technology with CGMs for a closed-loop AID system include:<\/p>\n